What is WuXi Biologics (Cayman) Revenue per Share?
WuXi Biologics (Cayman)'s revenue per share for the
six
months ended in Dec. 2023 was €0.25.
WuXi Biologics (Cayman)'s revenue per share for the trailing twelve months (TTM) ended in Dec. 2023 was €0.50.
Warning Sign:
WuXi Biologics (Cayman) Inc revenue growth has slowed down over the past 12 months.
During the past 12 months, the average Revenue Per Share Growth Rate of WuXi Biologics (Cayman) was 9.90% per year.
During the past 3 years, the average Revenue Per Share Growth Rate was 39.40% per year.
During the past 5 years, the average Revenue Per Share Growth Rate was 45.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.
The historical rank and industry rank for WuXi Biologics (Cayman)'s Revenue per Share or its related term are showing as below:
FRA:1FW2'
s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 39.4 Med: 52 Max: 65.3
Current: 39.4
During the past 10 years, WuXi Biologics (Cayman)'s highest 3-Year average Revenue Per Share Growth Rate was 65.30% per year. The lowest was 39.40% per year. And the median was 52.00% per year.
FRA:1FW2's 3-Year Revenue Growth Rate is ranked better than 82.67% of 779
companies
in the Biotechnology industry
Industry Median: 4
vs FRA:1FW2: 39.40
WuXi Biologics (Cayman) Revenue per Share Historical Data
The historical data trend for WuXi Biologics (Cayman)'s Revenue per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of WuXi Biologics (Cayman)'s Revenue per Share
For the Biotechnology subindustry, WuXi Biologics (Cayman)'s PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
WuXi Biologics (Cayman)'s PS Ratio Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, WuXi Biologics (Cayman)'s PS Ratio distribution charts can be found below:
* The bar in red indicates where WuXi Biologics (Cayman)'s PS Ratio falls into.
WuXi Biologics (Cayman) Revenue per Share Calculation
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
WuXi Biologics (Cayman)'s Revenue Per Share for the fiscal year that ended in Dec. 2023 is calculated as
Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.50
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WuXi Biologics (Cayman) (FRA:1FW2) Revenue per Share Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
WuXi Biologics (Cayman) Revenue per Share Related Terms
Thank you for viewing the detailed overview of WuXi Biologics (Cayman)'s Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
WuXi Biologics (Cayman) (FRA:1FW2) Business Description
WuXi Biologics is one of the largest global biologics CRDMOs. WuXi Biologics, incorporated in 2014 following the reorganization of WuXi PharmaTech, later known as WuXi AppTec, now has global revenue of CNY 15 billion. North American represented 55.6% of total revenue in 2022. It adopts the follow and win the molecule strategy by providing end-to-end services, from drug discovery to commercial manufacturing. It also adopts a global dual-sourcing strategy by providing drug products and large-scale drug substance manufacturing.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRA:1FW2 has been successfully added to your 